FDA Gives Clearance for Phase 1/2 Trial of Novel TRIM72 Agent in ALS

Backed by promising early data and mechanistic insights, SNUG01 enters clinical trials as the first TRIM72-based gene therapy candidate for ALS.:

Source: Neurology Read More